 Home > Medical News > Latest Medical News > The UK takes the lead in approving the use of Merck's oral anti-corona drug

The UK takes the lead in approving the use of Merck's oral anti-corona drug

 Last Update: 2021-11-11
 Source: Internet
 Author: User

Tags

what purpose food drug administration

drug hypersensitivity

quality healthcare

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The UK takes the lead in approving the use of Merck's oral anti-corona drug

The UK takes the lead in approving the use of Merck's oral anti-coronavirus drug

Xinhua News Agency, Beijing, November 4 (Reporter Zhang Ying) The Drugs and Healthcare Products Administration of the United Kingdom announced on the 4th that it has approved the oral anti-coronavirus drug monabiravir developed by Merck in the United States for certain patients with COVID-19
.

This is the world's first anti-coronavirus oral drug

The British Medicines and Health Products Administration issued a communiqué on the 4th that monabiravir has been approved for use in patients with mild to moderate symptoms of new coronary disease.
These patients have at least one risk factor for worsening serious illness, including obesity and age.
60 years old, diabetes and heart disease
.

Monabilavir was jointly developed by Merck and Richbuck Biomedicine.
It is a small-molecule broad-spectrum antiviral oral drug for RNA viruses that can inhibit the replication of the new coronavirus
.

The interim analysis data of the Phase III clinical trial announced by Merck in early October showed that the drug can reduce the risk of hospitalization or death of patients with mild to moderate symptoms of new crown by about 50%

The statement said that the UK regulators and the government's independent expert advisory group "human drugs committee would" carry out its safety, quality and effectiveness of the scrutiny, making it the first approved treatment of new infections crown oral antiviral drugs
.

The Communiqué quoted the British Secretary of Health Said Javid as saying that for the most vulnerable and immunosuppressed patients, approval of the drug will "change the rules of the game", and these people will soon be able to receive breakthrough treatments

Committee member

The United Kingdom is the first country in the world to officially approve the use of monabiravir to treat patients with new crowns
.

The European Medicines Agency has stated on October 5 that it will consider starting a rapid approval of monabiravir

Focus on the new crown pneumonia epidemic

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.